| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Actuate Therapeutics, Inc.
13D/A
ACTU · 005083100
|
49.8% |
6/30/2025
Event 6/27/2025
|
||||
| Bios Fund I, LP | 2.6% | |||||
| Bios Fund I QP, LP | 1.5% | |||||
| Bios Fund II, LP | 1.5% | |||||
| Bios Fund II QP, LP | 4.9% | |||||
| Bios Fund II NT, LP | 0.7% | |||||
| Bios Fund III, LP | 1.9% | |||||
| Bios Fund III QP, LP | 12.3% | |||||
| Bios Fund III NT, LP | 2.0% | |||||
| BP Directors, LP | 0.6% | |||||
| Bios Actuate Co-Invest I, LP | 1.5% | |||||
| Bios Actuate Co-Invest II, LP | 10.2% | |||||
| Bios Actuate Co-Invest III, LP | 2.8% | |||||
| Bios Clinical Opportunity Fund, LP | 6.2% | |||||
| Bios 2024 Co-Invest, LP | 1.3% | |||||
| Bios Equity Partners, LP | 4.6% | |||||
| Bios Equity Partners II, LP | 8.5% | |||||
| Bios Equity Partners III, LP | 29.2% | |||||
| Bios Equity Cof, LP | 7.4% | |||||
| Cavu Management, LP | 42.2% | |||||
| Bios Capital Management, LP | 49.5% | |||||
| Cavu Advisors, LLC | 42.2% | |||||
| Bios Advisors GP, LLC | 49.5% | |||||
| Leslie W. Kreis | 42.6% | |||||
| Aaron G.L. Fletcher | 49.8% | |||||
| Schedule 13G · 1 security · passive | ||||||
|
Rein Therapeutics, Inc.
13G/A
RNTX · 00887A204
|
10.0% |
5/8/2026
Event 5/6/2026
|
||||
| Bios Fund I, LP | 2.1% | |||||
| Bios Capital Management, LP | 10.0% | |||||
| Bios Fund II, LP | 0.5% | |||||
| Bios Fund II QP, LP | 1.7% | |||||
| Bios Fund II NT, LP | 0.2% | |||||
| Bios Equity Partners, LP | 0% | |||||
| Bios Clinical Opportunity Fund, LP | 3.0% | |||||
| Bios Fund III QP, LP | 1.7% | |||||
| Bios Fund III NT, LP | 0.3% | |||||
| Bios Advisors GP, LLC | 10.0% | |||||
| Bios Fund III, LP | 0.3% | |||||
| Bios Equity Cof, LP | 2.2% | |||||
| Bios Equity Partners II, LP | 2.4% | |||||
| Bios Equity Partners III, LP | 2.2% | |||||
| Cavu Advisors, LLC | 10.0% | |||||
| Cavu Management, LP | 10.0% | |||||
| Leslie W. Kreis | 10.0% | |||||
| Aaron G.L. Fletcher | 10.0% | |||||
| Bios Fund I QP, LP | 1.2% | |||||
| Bios LTI Co-Invest III QP, LP | 5.5% | |||||
| Bios LTI Co-Invest III, LP | 5.4% | |||||
| Bios LTI SPV II, LP | 1.9% | |||||
| Bios 2026 Co-Invest, LP | 1.3% | |||||
| Bios 2024 Co-Invest, LP | 0.7% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.